| Configuration: OncoVI 2026 publication configuration | Protocol: OncoVI three-class assessment: MTB selected expert reassessment Dataset: MTB selected expert reassessment | 80% Percent agreement (vs expert reassessment) percent · higher Uncertainty: Not reported by the source: not reported for this endpoint Coverage: Not reported scored / Not reported eligible | Author-reported evaluation · Source checkedMethods, coverage and sourceOncoVI: MTB selected expert reassessment Not reported Aggregation: Not reported Oncogenicity Variant Interpreter (OncoVI) Supports Harmonized Somatic Variant Interpretation in Precision Oncology · Results, MTB selected expert reassessment, expert_concordance; subgroup values correspond to Supplemental Table S6 |
|---|
| Configuration: OncoVI 2026 publication configuration | Protocol: OncoVI three-class assessment: MTB selected expert reassessment Dataset: MTB selected expert reassessment | 22% Percent agreement (prior mtb classification vs expert reassessment) percent · higher Uncertainty: Not reported by the source: not reported for this endpoint Coverage: Not reported scored / Not reported eligible | Author-reported evaluation · Source checkedMethods, coverage and sourceOncoVI: MTB selected expert reassessment Not reported Aggregation: Not reported Oncogenicity Variant Interpreter (OncoVI) Supports Harmonized Somatic Variant Interpretation in Precision Oncology · Results, MTB selected expert reassessment, prior_mtb_concordance; subgroup values correspond to Supplemental Table S6 |
|---|
| Configuration: OncoVI 2026 publication configuration | Protocol: OncoVI three-class assessment: MTB selected expert reassessment Dataset: MTB selected expert reassessment | 0.7 Correlation (correlation type not stated) unitless · higher Uncertainty: Not reported by the source: not reported for this endpoint Coverage: Not reported scored / Not reported eligible | Author-reported evaluation · Source checkedMethods, coverage and sourceOncoVI: MTB selected expert reassessment Not reported Aggregation: Not reported Oncogenicity Variant Interpreter (OncoVI) Supports Harmonized Somatic Variant Interpretation in Precision Oncology · Results, Figure 4C, concordant variants only |
|---|
| Configuration: Historical Erlangen MTB protein-function interpretation | Protocol: OncoVI three-class assessment: MTB selected expert reassessment Dataset: MTB selected expert reassessment | 34% Percent agreement (vs expert reassessment) percent · higher Uncertainty: Not reported by the source: not reported for this endpoint Coverage: Not reported scored / Not reported eligible | Author-reported evaluation · Source checkedMethods, coverage and sourceHistorical MTB agreement with expert oncogenicity reassessment Not reported Aggregation: Not reported Oncogenicity Variant Interpreter (OncoVI) Supports Harmonized Somatic Variant Interpretation in Precision Oncology · Results, validation data set, paragraph ending 46/135; Figure 4A |
|---|
| Configuration: Historical Erlangen MTB protein-function interpretation | Protocol: OncoVI three-class assessment: MTB selected expert reassessment Dataset: MTB selected expert reassessment | 46 Count (expert-concordant variants) count · unknown Uncertainty: Not reported by the source: not reported for this endpoint Coverage: Not reported scored / Not reported eligible | Author-reported evaluation · Source checkedMethods, coverage and sourceHistorical MTB agreement with expert oncogenicity reassessment Not reported Aggregation: Not reported Oncogenicity Variant Interpreter (OncoVI) Supports Harmonized Somatic Variant Interpretation in Precision Oncology · Results, validation data set, paragraph ending 46/135; Figure 4A |
|---|